focus -WSS

focus

author：explore 2025-10-02 10:38:50 - browse：2

Photo illustration of Chris Viehbacher -- biotech coverage from STAT — Chris Viehbacher took over as Biogen CEO in November. Suzanne Kreiter/Globe staff; Photo illustration Alex Hogan/STAT

This was supposed to be the new Biogen. When Chris Viehbacher, a respected pharmaceutical executive, took over as CEO in November, Wall Street saw him as a steadying force for the wayward company and a strong personality who would stand up to its quarrelsome board.

Instead, Biogen’s board has saddled Viehbacher with the first crisis of his tenure at the company. Alex Denner, a long-time director, nominated a biotech executive who is also the mother of his child to succeed him on the board, and Biogen chose not to disclose the couple’s relationship to shareholders, an omission that shocked people close to the company and undermined the notion that Biogen was changing for the better.

“It’s just disappointing to see after all the criticism that has been levied at the company over the last few years, there really seems to be no self-awareness going into this recommendation,” said Brian Skorney, a securities analyst at Baird who covers Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Inequities make cancer less preventable for women: report

focus

WSS

Pharmacists can make shortage drugs, but at what cost?

Mindstrong's demise and the future of mental health care

Covid vaccines: Private market messier than government rollout

Researchers explore possible ties between long Covid, menopause

Senator probes 340B programs at Cleveland Clinic, Bon Secours

Will Ozempic

Wikipedia

focus

focus

Medical records are filled with copy

After a drawn out lobbying fight, ARPA

United colonoscopy coverage change 'may cost lives,' doctors say

Kaiser Permanente unions announce official strike date

Alkermes shareholders re

How one patient went off dialysis — and others can too

After affirmative action ruling, medical educators look to 'holistic review'

Medicaid, Medicare dual

Jerome Adams on the need for new antivirals for Covid

NIH confirmation hearing shows politicization of research

Wikipedia

Data show record exodus of life scientists from academia

FDA gives detailed accounting of AI

Sudafed saga points to U.S. issues with evaluating older drugs

Covid vaccines: Private market messier than government rollout

STAT Summit: GSK CEO on pharma giant's new direction

FDA gives detailed accounting of AI

focus

knowledge

knowledge

knowledge